ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone949-419-0288
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.56 million
Profitability
Miscellaneous
Employees100
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Chromadex (NASDAQ:CDXC) Frequently Asked Questions
What is Chromadex's stock symbol?
Chromadex trades on the NASDAQ under the ticker symbol "CDXC."
How were Chromadex's earnings last quarter?
Chromadex Corp (NASDAQ:CDXC) posted its quarterly earnings data on Thursday, March, 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.01. The business earned $9.07 million during the quarter, compared to the consensus estimate of $9.21 million. Chromadex had a negative net margin of 105.57% and a negative return on equity of 90.20%. View Chromadex's Earnings History.
When is Chromadex's next earnings date?
What price target have analysts set for CDXC?
2 brokerages have issued 1-year price objectives for Chromadex's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Chromadex's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 79.5% from the stock's current price. View Analyst Price Targets for Chromadex.
What is the consensus analysts' recommendation for Chromadex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.
What are Wall Street analysts saying about Chromadex stock?
Here are some recent quotes from research analysts about Chromadex stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (3/11/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 24x EV- to-EBITDA multiple to 2020 EBITDA per share of $0.45, discounted back at 12%, which yields a price objective of approximately $8.00 per share." (9/10/2018)
Has Chromadex been receiving favorable news coverage?
Media headlines about CDXC stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chromadex earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the stock's share price in the near future.
Who are some of Chromadex's key competitors?
Some companies that are related to Chromadex include CV Sciences (CVSI), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), Cyanotech (CYAN), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), FitLife Brands (FTLF), True Drinks (TRUU), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).
What other stocks do shareholders of Chromadex own?
Who are Chromadex's key executives?
Chromadex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
- Mr. Robert N. Fried, CEO & Director (Age 59)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
- Mr. Ben Shichman, Chief Technology Officer
- Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation
Who are Chromadex's major shareholders?
Chromadex's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tieton Capital Management LLC (1.98%), Northern Trust Corp (0.75%), Geode Capital Management LLC (0.63%), Geode Capital Management LLC (0.63%), Bank of New York Mellon Corp (0.23%) and Sargent Investment Group LLC (0.19%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen A Block and Stephen R Allen. View Institutional Ownership Trends for Chromadex.
Which institutional investors are selling Chromadex stock?
CDXC stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., MML Investors Services LLC, LPL Financial LLC and Knoll Capital Management LP. Company insiders that have sold Chromadex company stock in the last year include Frank L Jaksch Jr and Stephen A Block. View Insider Buying and Selling for Chromadex.
Which institutional investors are buying Chromadex stock?
CDXC stock was bought by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Bank of New York Mellon Corp, Geode Capital Management LLC, Geode Capital Management LLC, Rhumbline Advisers, Tieton Capital Management LLC, Northern Trust Corp and Resources Investment Advisors Inc.. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Insider Buying and Selling for Chromadex.
How do I buy shares of Chromadex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chromadex's stock price today?
One share of CDXC stock can currently be purchased for approximately $3.90.
How big of a company is Chromadex?
Chromadex has a market capitalization of $215.63 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.
What is Chromadex's official website?
How can I contact Chromadex?
Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 949-419-0288 or via email at [email protected]
MarketBeat Community Rating for Chromadex (NASDAQ CDXC)
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
